ARTICLE | Clinical News
Ninlaro ixazomib regulatory update
September 26, 2016 7:00 AM UTC
EMA’s CHMP recommended conditional approval of Ninlaro ixazomib from Takeda in combination with Revlimid lenalidomide and dexamethasone to treat relapsed or refractory multiple myeloma (MM) in patien...